FrancophonIA/ELRC3.0 huggingface dataset:
English: Pimobendan is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilating properties.
Croatian: Pimobendan je nesimpatomimetička i neglikozidna inotropna tvar s potentnim vazodilatacijskim svojstvima.
English: Benazepril hydrochloride is a prodrug which is hydrolysed in vivo to its active metabolite, benazeprilat.
Croatian: Benazepril hidroklorid je prolijek koji se hidrolizira in vivo u njegov aktivni metabolit, benazeprilat.
English: Levels of benazepril decline quickly as the drug is partially metabolised by liver enzymes to benazeprilat.
Croatian: Razine benazeprila opadaju brzo kako se veterinarsko-medicinski proizvod djelomično metabolizira putem jetrenih enzima u benazeprilat.
English: Benazepril hydrochloride is partially metabolised by liver enzymes to the active metabolite benazeprilat.
Croatian: Benazepril hidroklorid se djelomično metabolizira jetrenim enzimima u aktivni metabolit benazeprilat.
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each tablet contains
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
English: The main active metabolite of pimobendan is eliminated with a plasma elimination half-life of 2.6 h. Pimobendan is excreted principally in the faeces and to a lesser extent in the urine.
Croatian: Glavni aktivni metabolit pimobendana eliminira se s plazmatskim poluživotom eliminacije od 2,6 sati.
English: FORTEKOR PLUS 5 mg/10 mg tablets: 30 tablets or 60 tablets.
Croatian: FORTEKOR PLUS 5 mg/10 mg tablete: 30 ili 60 tableta.
English: NAME OF THE MARKETING AUTHORISATION HOLDER Elanco
Croatian: NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET Elanco
English: Use during pregnancy, lactation:
Croatian: Primjena tijekom graviditeta i laktacije
English: FORTEKOR PLUS 1.25 mg/2.5 mg tablets: 30 tablets or 60 tablets.
Croatian: FORTEKOR PLUS 1,25 mg/2,5 mg tablete: 30 ili 60 tableta.
English: 5 mg/10 mg tablets: pack sizes of 30 or 60 tablets.
Croatian: Tablete od 5 mg/10 mg: veličine pakovanja od 30 ili 60 tableta.
English: 1.25 mg/2.5 mg tablets: pack sizes of 30 or 60 tablets.
Croatian: Tablete od 1,25 mg/2,5 mg: veličine pakovanja od 30 ili 60 tableta.
English: Artificial Special Dry Flavour Basic butylated methacrylate copolymer Copovidone
Croatian: Bazični butilirani metakrilat kopolimer
English: It is therefore recommended to monitor plasma potassium levels when using FORTEKOR PLUS in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.
Croatian: FORTEKORA PLUS u kombinaciji s diureticima koji štede kalij zbog rizika od hiperkalijemije.
English: Lactose monohydrate Magnesium stearate
Croatian: Smeđi željezov oksid E172 Laktoza monohidrat Magnezijev stearat Kukuruzni škrob
English: NAME OF THE VETERINARY MEDICINAL PRODUCT FORTEKOR PLUS 1.25 mg/2.5 mg tablets for dogs FORTEKOR PLUS 5 mg/10 mg tablets for dogs
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA FORTEKOR PLUS 1,25 mg/2,5 mg tablete za pse FORTEKOR PLUS 5 mg/10 mg tablete za pse
English: Benazepril and benazeprilat are extensively bound to plasma proteins (8590%), and in the tissues they are found mainly in the lung, liver and kidney.
Croatian: Benazepril i benazeprilat opsežno se vežu na proteine plazme (85
English: The recommended dose range for FORTEKOR PLUS is 0.25-0.5 mg pimobendan per kg bodyweight and 0.5-1 mg benazepril hydrochloride per kg bodyweight divided into two daily doses.
Croatian: Preporučeni raspon doza za FORTEKOR PLUS je 0,25 - 0,5 mg pimobendana po kg tjelesne težine te
English: Active substances:
Croatian: Svaka tableta sadrži: Djelatne tvari:
English: The plasma elimination half-life of benazepril hydrochloride and benazeprilat, when dosed with FORTEKOR PLUS tablets is 0.36 h and 8.36 h, respectively.
Croatian: Poluživot eliminacije benazepril hidroklorida i benazeprilata iz plazme, kada se dozira s tabletama
English: FORTEKOR PLUS 1.25 mg/2.5 mg tablets for dogs FORTEKOR PLUS 5 mg/10 mg tablets for dogs
Croatian: UPUTA O VMP ZA FORTEKOR PLUS 1,25 mg/2,5 mg tablete za pse FORTEKOR PLUS 5 mg/10 mg tablete za pse
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Elanco GmbHHeinz-Lohmann-Str. 4
Croatian: 15. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET Elanco GmbH
English: Elanco GmbH
Croatian: Nositelj odobrenja za stavljanje u promet: Elanco GmbH
English: PACKAGE SIZE 30 tablets
Croatian: Jačina i broj tableta za primjenu
English: Pimobendan:
Croatian: NUSPOJAVE Pimobendan
English: Excipients:
Croatian: Lot: {broj}
English: Hypromellose
Croatian: Kopovidon
English: Dibutyl sebacate
Croatian: I SAŽETAK OPISA SVOJSTAVA
English: The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC.
Croatian: Informacija o lijeku može se zatim revidirati od strane nacionalnih mjerodavnih tijela u suradnji s referentnom državom članicom, ako je potrebno, sukladno postupku propisanom u poglavlju 4 naslova III Direktive 2001/83/EC.
English: Established congestive heart failure (NYHA II-IV), ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
Croatian: Utvrđeno kongestivno zatajenje srca (NYHA II-IV), ishemijska bolest srca, bolest perifernih arterija i/ili cerebrovaskularna bolest.
English: Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4 Special warnings and precautions for use).
Croatian: Nuspojave se mogu minimizirati primjenom najniže učinkovite doze tijekom najkraćeg vremenskog razdoblja potrebnog za kontrolu simptoma (vidjeti dio 4.4 Posebna upozorenja i mjere opreza pri uporabi).
English: Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with diclofenac after careful consideration.
Croatian: Bolesnici sa značajnim čimbenicima rizika za nastanak kardiovaskularnih događaja (npr. hipertenzija, hiperlipidemija, diabetes mellitus, pušenje) smiju se liječiti diklofenakom tek nakon pažljivog razmatranja.
English: As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used.
Croatian: S obzirom da se kardiovaskularni rizici kod primjene diklofenaka mogu povećati s dozom i trajanjem izloženosti, potrebno je primjenjivati najmanju moguću učinkovitu dozu i uz najkraće moguće trajanje.
English: Side effects may be minimised by using the lowest effective dose for the shortest duration necessary.
Croatian: Nuspojave se mogu umanjiti primjenom najniže učinkovite doze tijekom najkraćeg neophodnog vremenskog razdoblja.
English: The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically.
Croatian: U bolesnika se periodično mora ponovno procijeniti je li potrebno ublažavanje simptoma te odgovor na terapiju.
English: Section 2 ‘What you need to know before you take <diclofenac containing medicinal product> [The wording below should be inserted in the relevant sections]
Croatian: Dio 2 Što morate znati prije nego počnete uzimati <lijek koji sadrži diklofenak>
English: Annex III Amendments to relevant sections of the summary of product characteristics and package leaflet
Croatian: Dodatak III Izmjene odgovarajućih dijelova sažetka opisa svojstava lijeka i uputa o lijeku
English: Clinical trial and epidemiological data consistently point towards an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) associated with the use of diclofenac, particularly at high dose (150mg daily) and in long term treatment.
Croatian: Kliničko ispitivanje i epidemiološki podaci dosljedno ukazuju na povećan rizik od arterijskih trombotičnih događaja (na primjer infarkt miokarda ili moždani udar) povezanih s primjenom diklofenaka, osobito pri visokoj dozi (150 mg dnevno) te tijekom dugotrajnog liječenja (vidjeti dijelove 4.3 i 4.4 za Kontraindikacije i Posebna upozorenja i mjere opreza pri uporabi).
English: This Summary of Product Characteristics and package leaflet is the outcome of the referral procedure.
Croatian: Sažetak opisa svojstava lijeka i Uputa o lijeku rezultat je arbitražnog postupka.
English: If you have diabetes
Croatian: Uputa o lijeku
English: Do not use diclofenac if you have established heart disease and /or cerebrovascular disease e.g. if you have had a heart attack, stroke, mini-stroke (TIA) or blockages to blood vessels to the heart or brain or an operation to clear or bypass blockages if you have or have had problems with your blood circulation (peripheral arterial disease)
Croatian: Ako Vam je utvrđena bolest srca i /ili cerebrovaskularna bolest npr. ako ste pretrpjeli srčani udar, moždani udar, mali moždani udar (TIA - tranzitorna ishemijska ataka) ili su Vam začepljene krvne žile koje vode do srca ili mozga, ili ste imali operativni zahvat radi uklanjanja ili premošćivanja začepljenja.
English: Section 4.4 Special warnings and precautions for use: [The wording below should be inserted in this section]
Croatian: Dio 4.4 Posebna upozorenja i mjere opreza pri uporabi: [U ovaj dio potrebno je umetnuti donji tekst]
English: If you have angina, blood clots, high blood pressure, raised cholesterol or raised triglycerides
Croatian: Vam primjeni diklofenak, svakako recite Vašem liječniku ako pušite ako imate dijabetes ako imate anginu, krvne ugruške, povišeni krvni tlak, povišen kolesterol ili povišene trigliceride
English: Section 4.3 Contraindications: [The wording below should be inserted in this section]
Croatian: Dio 4.3 Kontraindikacije: [U ovaj dio potrebno je umetnuti donji tekst]
English: A. Summary of Product Characteristics Section 4.2 Posology and method of administration: [The wording below should be inserted in this section]
Croatian: Sažetak opisa svojstava lijeka Dio 4.2 Doziranje i način primjene: [U ovaj dio potrebno je umetnuti sljedeći tekst]
English: Section 4.8 Undesirable effects: [The wording below should be inserted in this section]
Croatian: Dio 4.8 Nuspojave: [U ovaj dio potrebno je umetnuti sljedeći tekst]
English: Medicinal product no longer authorised
Croatian: Lijek više nije odobren
English: Content (concentration)
Croatian: <Sastav (koncentracija)>
English: Strength Pharmaceutical
Croatian: Doza Farmaceutski oblik Put primjene Unutarnje pakovanje
English: 23 May 2014 EMA/232003/2014 EMEA/H/C/000560 EMEA/H/C/000561
Croatian: EMA/232003/2014 EMEA/H/C/000560 EMEA/H/C/000561
English: Protelos/Osseor has been authorised since September 2004.
Croatian: Protelos/Osseor odobren je od rujna 2004.
English: The full European Public Assessment Report for Protelos/Osseor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku Protelos/Osseor možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: In addition, the Committee had some concerns about the way in which the loss of cartilage had been evaluated.
Croatian: Nadalje, Povjerenstvo je izrazilo zabrinutost o načinu na koji je ocijenjen gubitak hrskavice.
English: The applicant presented data from one main study involving 1,683 patients with osteoarthritis of the knee.
Croatian: Podnositelj zahtjeva dostavio je podatke iz jednog glavnog ispitivanja koje je obuhvatilo 1 683 bolesnika s osteoartritisom koljena.
English: What is Protelos/Osseor?
Croatian: Što je Protelos/Osseor?
English: They are available as sachets containing strontium ranelate (2 g) as granules to be made up into a suspension to be taken by mouth.
Croatian: Dostupni su kao vrećice koje sadrže stroncijev ranelat (2 g) kao granule koje se miješaju u suspenziju koja se uzima na usta.
English: In this study, strontium ranelate 1 or 2 g was compared with placebo (a dummy treatment).
Croatian: U tom ispitivanju, stroncijev ranelat u dozi od 1 ili 2 g uspoređen je s placebom (lažnim liječenjem).
English: It is currently used to treat severe osteoporosis (a disease that makes bones fragile) in post-menopausal women and men who have a high risk of fracture.
Croatian: Trenutno se koristi za liječenje teške osteoporoze (bolesti koja čini kosti lomljivima) u žena u postmenopauzi i muškaraca izloženih velikom riziku od fraktura.
English: There are no consequences on the use of Protelos/Osseor in its authorised indications.
Croatian: Nema posljedica za korištenje lijeka Protelos/Osseor u odobrenim indikacijama.
English: The main measure of effectiveness was the effect in slowing the loss of cartilage from the joint as measured by X-rays after 3 years of treatment.
Croatian: Glavna mjera djelotvornosti bilo je djelovanje na usporavanje gubitka hrskavice u zglobu što se mjeri rendgenom nakon 3 godine liječenja.
English: Protelos and Osseor are identical medicines that contain the active substance strontium ranelate.
Croatian: Protelos i Osseor su identični lijekovi koji sadrže djelatnu tvar stroncijev ranelat.
English: What did the company present to support its applications?
Croatian: Što je tvrtka dostavila da bi poduprla zahtjeve?
English: After the CHMP had assessed the company's responses to the last round of questions, there were still some unresolved issues.
Croatian: Nakon što je CHMP ocijenio odgovore tvrtke na posljednju skupinu pitanja, još su uvijek postojale neke nedoumice.
English: In osteoarthritis, the cartilage, a smooth layer that lines the joints and helps them to move easily, is gradually lost, and the bone underneath becomes damaged and exposed.
Croatian: U slučaju osteoartritisa, hrskavica, glatki sloj koji oblaže zglobove i pomaže im pri kretanju, postupno nestaje, a kost ispod hrskavice se oštećuje i izlaže.
English: The CHMP noted that the size of the benefit seen in the study was small and the long-term benefit unclear, whereas the medicine had an established risk of serious side effects.
Croatian: CHMP je zaključio da je razmjer koristi uočen u ispitivanju skroman i da dugoročna korist nije jasna, dok je za lijek utvrđen rizik ozbiljnih nuspojava.
English: The applications were withdrawn after the CHMP had evaluated the documentation provided by the company and formulated lists of questions.
Croatian: Zahtjevi su povučeni nakon što je CHMP ocijenio dokumentaciju koju je tvrtka dostavila te je sastavio popise pitanja.
English: How far into the evaluation were the applications when they were withdrawn?
Croatian: U kojoj je fazi bila ocjena zahtjeva kada su povučeni?
English: What is happening with Protelos/Osseor for the treatment of osteoporosis?
Croatian: Što se događa s lijekom Protelos/Osseor kada je riječ o liječenju osteoporoze?
English: In its letter notifying the Agency of the withdrawal of the applications, the company stated that the withdrawal was due to the fact that the data so far available were insufficient to address the CHMP's concerns.
Croatian: U dopisu tvrtke kojim se obavještava Agenciju o povlačenju zahtjeva, tvrtka je navela kako povlači zahtjeve zbog činjenice da do sada dostupni podaci nisu dostatni za uklanjanje zabrinutosti CHMP-a.
English: On 21 March 2014, Les Laboratoires Servier officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its applications to extend the indication of Protelos/Osseor to include the treatment of osteoarthritis of the knee and hip.
Croatian: Dana 21. ožujka 2014., Les Laboratoires Servier službeno je obavijestio Povjerenstvo za humane lijekove (CHMP) kako želi povući svoje zahtjeve za produljenje indikacije za lijek Protelos/Osseor za liječenje osteoartritisa koljena i kuka.
English: The company informed the CHMP that there are no consequences for any ongoing clinical trials with Protelos/Osseor.
Croatian: Tvrtka je obavijestila CHMP da nema posljedica za klinička ispitivanja lijeka Protelos/Osseor koja su trenutno u tijeku.
English: Protelos/Osseor was also expected to be used to treat osteoarthritis (a long-term disease that damages joints and makes them stiff and painful) in the knee and hip.
Croatian: Protelos/Osseor trebao se također koristiti za liječenje osteoartritisa (dugotrajne bolesti koja oštećuje zglobove te ih čini krutima i bolnima) u koljenu i kuku.
English: What were the reasons given by the company for withdrawing the applications?
Croatian: Koje je razloge za povlačenje zahtjeva navela tvrtka?
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Protelos/Osseor in the treatment of osteoarthritis did not outweigh its risks.
Croatian: Stoga je u trenutku povlačenja CHMP smatrao da koristi lijeka Protelos/Osseor u liječenju osteoartritisa ne nadmašuju s njim povezane rizike.
English: Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Protelos/Osseor could not have been approved for the treatment of osteoarthritis.
Croatian: Na temelju pregleda podataka te odgovora tvrtke na popise pitanja CHMP-a, u trenutku povlačenja CHMP je smatrao da postoje problemi te je njegovo privremeno mišljenje bilo da nije moguće dati odobrenje za Protelos/Osseor za liječenje osteoartritisa.
English: Strontium ranelate, the active substance in Protelos/Osseor, is expected to stimulate formation of new cartilage and reduce bone breakdown.
Croatian: Stroncijev ranelat, djelatna tvar lijeka Protelos/Osseor, trebao je poticati formiranje nove hrskavice i smanjiti razgradnju kostiju.
English: How is Protelos/Osseor expected to work?
Croatian: Kako je Protelos/Osseor trebao djelovati?
English: What was Protelos/Osseor expected to be used for?
Croatian: Za što se Protelos/Osseor trebao koristiti?
English: stiffness when the joint moves.
Croatian: To uzrokuje bol i ukočenost prilikom pomicanja zgloba.
English: Invented Strength Pharmaceutical Form Route of Administration
Croatian: Doza Farmaceutski oblik Put primjene Unutarnje pakovanje
English: Packaging name
Croatian: Sastav
English: Intralesional use vial (glass)
Croatian: Intralezijski bočica (staklena)
English: Pharmaceutica l Form
Croatian: Farmaceutski oblik
English: 5 million cells/ml Suspension for injection
Croatian: 5 milijuna stanica/ml
English: This will help to protect against the diseases caused by these viruses.
Croatian: Ovo pomaže pri zaštiti protiv bolesti koje uzrokuju ovi virusi.
English: This summary was last updated in 05-2014.
Croatian: Sažetak je posljednji put ažuriran: 05.2014.
English: Gardasil is given according to official recommendations.
Croatian: Gardasil se primjenjuje u skladu sa službenim preporukama.
English: These virus-like particles are not capable of causing infection.
Croatian: Ove čestice slične virusu ne mogu uzrokovati infekciju.
English: • genital warts.
Croatian: • genitalnih bradavica.
English: The women were followed up for around three years after the third dose of the vaccine.
Croatian: Žene su praćene otprilike tri godine nakon treće doze cjepiva.
English: The vaccine is given as an injection into a muscle, preferably in the shoulder or the thigh.
Croatian: Cjepivo se primjenjuje kao injekcija u mišić, po mogućnosti u rame ili bedro.
English: The full EPAR for Gardasil can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Gardasil nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: There are more than 100 types of papillomavirus, some of which are associated with genital cancers.
Croatian: Postoji više od 100 tipova papilomavirusa, od kojih su neki povezani s genitalnim rakovima.
English: These same three doses can also be used in individuals aged nine to thirteen years.
Croatian: Ove iste tri doze mogu se također primijeniti u osoba u dobi od devet do trinaest godina.
English: After vaccination, the immune system is able to produce antibodies more quickly when it is exposed to the real viruses.
Croatian: Nakon cijepljenja, imunosni sustav može brže proizvoditi protutijela nakon što je izložen stvarnim virusima.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Gardasil on 20 September 2006.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Gardasil vrijedi na prostoru Europske unije od 20. rujna 2006.
English: The vaccine also contains an ‘adjuvant' (a compound containing aluminium) to stimulate a better response.
Croatian: Cjepivo također sadrži „adjuvans” (spoj koji sadrži aluminij) za poticanje boljeg odgovora.
English: The proteins are assembled in ‘virus-like particles' (structures that look like HPV, so that the body can recognise them easily).
Croatian: Proteini se skupljaju u „čestice slične virusu” (strukture koje izgledaju poput HPV-a, tako da ih tijelo može lakše prepoznati).
English: Human papillomaviruses are viruses that cause warts and abnormal tissue growth.
Croatian: Humani papilomavirusi su virusi koji uzrokuju bradavice i abnormalni rast tkiva.
English: Patients who show signs of an allergy after a dose of Gardasil should not receive further doses of the vaccine.
Croatian: Bolesnici koji pokazuju znakove alergije nakon doze lijeka Gardasil ne smiju primiti daljnje doze cjepiva.
English: Vaccination should be postponed in patients who are ill with a high fever.
Croatian: Cijepljenje se mora odgoditi u osoba koje su bolesne i imaju vrućicu.
English: Gardasil is used in males and females from the age of nine years to protect against the following conditions caused by specific types of human papillomavirus (HPV):
Croatian: Gardasil se koristi u muškaraca i žena od devete godine starosti za prevenciju sljedećih stanja uzrokovanih specifičnim tipovima humanoga papilomavirusa (HPV):
English: What measures are being taken to ensure the safe and effective use of Gardasil?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Gardasil?
English: It is a suspension for injection that contains purified proteins for four types of the human papillomavirus (types 6, 11, 16 and 18).
Croatian: To je suspenzija za injektiranje koja sadrži pročišćene proteine za četiri tipa ljudskog papilomavirusa (tipovi 6, 11, 16 i 18).
English: There should always be at least one month between the first and the second doses, and at least three months between the second and the third, and all doses should be given within a year.
Croatian: Uvijek treba proteći najmanje mjesec dana između prve i druge doze te najmanje tri mjeseca između druge i treće doze, a sve se doze moraju primijeniti u roku od godine dana.
English: Gardasil is a vaccine.
Croatian: Gardasil je cjepivo.
English: This document is a summary of the European public assessment report (EPAR) for Gardasil.
Croatian: Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Gardasil.
English: It is recommended that individuals who receive the first dose of Gardasil should complete the dosing regimen with Gardasil.
Croatian: Preporuča se da pojedinci koji prime prvu dozu lijeka Gardasil završe cjelokupan režim doziranja lijekom Gardasil.
English: • precancerous lesions (growths) in the cervix, vulva or vagina and anus;
Croatian: • premalignih lezija (izraslina) u grliću maternice, vulvi, vagini i anusu
English: If the second dose is given earlier than six months after the first dose, a third dose should always be given.
Croatian: Ako se druga doza daje prije proteka 6 mjeseci nakon prve doze, uvijek se mora dati treća doza.
English: All papillomaviruses have a shell, or ‘capsid', that is made up of proteins called ‘L1 proteins'.
Croatian: Svi papilomavirusi imaju ovojnicu, ili „kapsidu”, koja je izgrađena od proteina naziva „L1 proteini”.